Format

Send to

Choose Destination
J Invest Dermatol. 2013 Mar;133(3):642-646. doi: 10.1038/jid.2012.388. Epub 2012 Nov 29.

Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage.

Author information

1
Divisions of Dermatology and Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, Washington, USA.
2
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
3
Clinical Data Systems, Fountain Valley, California, USA.
4
Divisions of Dermatology and Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, Washington, USA; Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
5
Divisions of Dermatology and Medical Oncology, Department of Internal Medicine, University of Washington, Seattle, Washington, USA. Electronic address: pnghiem@uw.edu.

Abstract

Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy linked to a contributory virus (Merkel cell polyomavirus). Multiple epidemiologic studies have established an increased incidence of MCC among persons with systemic immune suppression. Several forms of immune suppression are associated with increased MCC incidence, including hematologic malignancies, HIV/AIDS, and immunosuppressive medications for autoimmune disease or transplant. Indeed, immune-suppressed individuals represent ∼10% of MCC patients, a significant overrepresentation relative to the general population. We hypothesized that immune-suppressed patients may have a poorer MCC-specific prognosis and examined a cohort of 471 patients with a combined follow-up of 1,427 years (median 2.1 years). Immune-suppressed patients (n=41) demonstrated reduced MCC-specific survival (40% at 3 years) compared with patients with no known systemic immune suppression (n=430; 74% MCC-specific survival at 3 years). By competing risk regression analysis, immune suppression was a stage-independent predictor of worsened MCC-specific survival (hazard ratio 3.8, P<0.01). Thus, immune-suppressed individuals have both an increased chance of developing MCC and poorer MCC-specific survival. It may be appropriate to follow these higher-risk individuals more closely, and, when clinically feasible, there may be a benefit of diminishing iatrogenic systemic immune suppression.

PMID:
23190897
PMCID:
PMC3570636
DOI:
10.1038/jid.2012.388
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center